Barth-Jaeggi Tanja, Steinmann Peter, Mieras Liesbeth, van Brakel Wim, Richardus Jan Hendrik, Tiwari Anuj, Bratschi Martin, Cavaliero Arielle, Vander Plaetse Bart, Mirza Fareed, Aerts Ann
Swiss Tropical and Public Health Institute, Basel, Switzerland.
University of Basel, Basel, Switzerland.
BMJ Open. 2016 Nov 17;6(11):e013633. doi: 10.1136/bmjopen-2016-013633.
The reported number of new leprosy patients has barely changed in recent years. Thus, additional approaches or modifications to the current standard of passive case detection are needed to interrupt leprosy transmission. Large-scale clinical trials with single dose rifampicin (SDR) given as post-exposure prophylaxis (PEP) to contacts of newly diagnosed patients with leprosy have shown a 50-60% reduction of the risk of developing leprosy over the following 2 years. To accelerate the uptake of this evidence and introduction of PEP into national leprosy programmes, data on the effectiveness, impact and feasibility of contact tracing and PEP for leprosy are required. The leprosy post-exposure prophylaxis (LPEP) programme was designed to obtain those data.
The LPEP programme evaluates feasibility, effectiveness and impact of PEP with SDR in pilot areas situated in several leprosy endemic countries: India, Indonesia, Myanmar, Nepal, Sri Lanka and Tanzania. Complementary sites are located in Brazil and Cambodia. From 2015 to 2018, contact persons of patients with leprosy are traced, screened for symptoms and assessed for eligibility to receive SDR. The intervention is implemented by the national leprosy programmes, tailored to local conditions and capacities, and relying on available human and material resources. It is coordinated on the ground with the help of the in-country partners of the International Federation of Anti-Leprosy Associations (ILEP). A robust data collection and reporting system is established in the pilot areas with regular monitoring and quality control, contributing to the strengthening of the national surveillance systems to become more action-oriented.
Ethical approval has been obtained from the relevant ethics committees in the countries. Results and lessons learnt from the LPEP programme will be published in peer-reviewed journals and should provide important evidence and guidance for national and global policymakers to strengthen current leprosy elimination strategies.
近年来,新麻风病患者的报告数量几乎没有变化。因此,需要采取额外的方法或对当前被动病例发现标准进行调整,以阻断麻风病传播。对新诊断麻风病患者的接触者给予单剂量利福平(SDR)进行暴露后预防(PEP)的大规模临床试验表明,在接下来的2年里,患麻风病的风险降低了50%-60%。为了加快采用这一证据并将PEP引入国家麻风病防治规划,需要有关麻风病接触者追踪和PEP的有效性、影响及可行性的数据。麻风病暴露后预防(LPEP)项目旨在获取这些数据。
LPEP项目在印度、印度尼西亚、缅甸、尼泊尔、斯里兰卡和坦桑尼亚等几个麻风病流行国家的试点地区评估SDR进行PEP的可行性、有效性和影响。补充地点位于巴西和柬埔寨。2015年至2018年,对麻风病患者的接触者进行追踪,筛查症状并评估接受SDR的资格。该干预措施由国家麻风病防治规划实施,根据当地情况和能力进行调整,并依靠现有人力和物力资源。在国际抗麻风病协会联盟(ILEP)的国内合作伙伴帮助下在当地进行协调。在试点地区建立了一个强大的数据收集和报告系统,进行定期监测和质量控制,有助于加强国家监测系统,使其更具行动导向性。
已获得各国相关伦理委员会的伦理批准。LPEP项目的结果和经验教训将在同行评审期刊上发表,并应为国家和全球政策制定者加强当前的麻风病消除战略提供重要证据和指导。